Sapir Venture Partners
VC Fund
Sapir Venture Partners is a VC fund focused on Software and Biotechnology. Early Stage VC
- Total investments:
- 22
- Last investment:
- Lead investor:
- 23%
Last updated:
For AI agents: llms.txt
Industries Sapir Venture Partners invests in
Stages Sapir Venture Partners invests in
Countries Sapir Venture Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1.3M–$10M
- Pre-Seed
- $305k–$800k
- Series A
- $10M–$40M
Investment Focus
Industry
- Software 5 (23%)
- Biotechnology 4 (18%)
- Analytics 3 (14%)
- Life Science 3 (14%)
- Information Technology 3 (14%)
Stage
- Seed 12 (55%)
- Pre-Seed 6 (27%)
- Series A 3 (14%)
Country
- Israel 8 (36%)
- United States 7 (32%)
- United Kingdom 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Aaron Zucker
Founder & Managing Partner
|
Founder & Managing Partner | Total investments: 4 | Find email | |
Gil Eyal
Startup Mentor
|
Startup Mentor | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Lidwave’s deep-tech solution revolutionizes 3D sensing and the verticals relying on it by examining the biggest challenge in LiDAR technology from a new perspective, free of bandwidth limitations. | $10M / Seed / Oct 14, 2024 | ||
| Enzymit is creating a new transformation layer for manufacturing by combining computational enzyme design, deep learning, and a proprietary high-throughput discovery platform. We develop novel enzymatic pathways and run them in controllable cell-free production systems. This approach merges the selectivity of biology with the precision ofchemistry, enabling cleaner and more efficient production. Our platform has been validated with pharmaceutical-grade hyaluronic acid (HA), produced at kilogram scale with superior consistency and purity compared to fermentation. We are now advancing toward commercial HA supply while expanding the platform to products like heparin and human milk oligosaccharides (HMOs). | $10M / Series A / Sep 25, 2024 | ||
| Enzymit is creating a new transformation layer for manufacturing by combining computational enzyme design, deep learning, and a proprietary high-throughput discovery platform. We develop novel enzymatic pathways and run them in controllable cell-free production systems. This approach merges the selectivity of biology with the precision ofchemistry, enabling cleaner and more efficient production. Our platform has been validated with pharmaceutical-grade hyaluronic acid (HA), produced at kilogram scale with superior consistency and purity compared to fermentation. We are now advancing toward commercial HA supply while expanding the platform to products like heparin and human milk oligosaccharides (HMOs). | $5M / Seed / Jan 01, 2022 | ||
| DeepCuris builds an AI engine for small-molecule drug discovery. | $40M / Series A / Nov 08, 2021 | ||
| NeuoKaire (formerly Genetika+) is developing a personalized medical testing tool to better treat depression by helping physicians find the best drug therapy for their patients. The Genetika+ test uses innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing. | $10M / Series A / Sep 30, 2021 | ||
| Developing technology to fight mosquitoes with mosquitoes. | $3M / Seed / Jun 11, 2021 | ||
| Miter | $770K / Pre-Seed / May 01, 2021 | ||
| OUR MISSION Fabric is on a mission to create a world where everyone belongs, one in-person interaction at a time. We do this by augmenting shared experiences, starting with the number one industry that brings people together: Sports.OUR TEAM Fabric’s team is a diverse group of technologists, entrepreneurs, humanists, executives, mathematicians,and designers who are devoted to creating a world where everyone belongs through the creation of the world’s most accessible and innovative technology platform.OUR PLATFORM Fabric is a venture-backed geospatial web3 platform for sports teams and leagues. Our platform transforms the fan experience by delivering immersive real-time AR, blockchain, social, and gaming experiences, powered by no-code tools and an AI engine that understands the team’s needs.Fabric Spaces transform smartphones into an interactive and social 3D jumbotron in every fan's pocket, unlocking a new layer of the in-stadium experience. Fabric transports fans to the unlimited possibilities that come from the blending of physical and digital worlds all under the official banner of their favorite team.We call this the Reality-First Metaverse™, where fans join the team. | $3.9M / Seed / Apr 16, 2021 | ||
| Suridata’s SaaS Security platform enables organizations to secure the use of SaaS applications. Companies rely on our solution to identify risks of misconfigurations, third-party integrations, and users' access. Once risks have been identified, the platform provides a remediation process according to best practices and security frameworks. Thecomprehensive point of view of Suridata’s solution ensures risk reduction across dozens of critical SaaS applications. | Seed / Jan 26, 2021 | ||
| Enzymit is creating a new transformation layer for manufacturing by combining computational enzyme design, deep learning, and a proprietary high-throughput discovery platform. We develop novel enzymatic pathways and run them in controllable cell-free production systems. This approach merges the selectivity of biology with the precision ofchemistry, enabling cleaner and more efficient production. Our platform has been validated with pharmaceutical-grade hyaluronic acid (HA), produced at kilogram scale with superior consistency and purity compared to fermentation. We are now advancing toward commercial HA supply while expanding the platform to products like heparin and human milk oligosaccharides (HMOs). | $500K / Pre-Seed / Jun 01, 2020 | ||
| See all 22 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Sapir Venture Partners invest in?
Sapir Venture Partners invests primarily in Software, Biotechnology and Analytics startups, most often at Seed and Pre-Seed stage. Most of the 22 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Sapir Venture Partners invest in?
Sapir Venture Partners typically joins rounds of $1.3M–$10M at Seed, $305k–$800k at Pre-Seed and $10M–$40M at Series A. These are whole funding-round sizes, not Sapir Venture Partners's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Sapir Venture Partners took part in.
How do I contact Sapir Venture Partners?
Public channels for Sapir Venture Partners include X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Sapir Venture Partners?
The team at Sapir Venture Partners includes Aaron Zucker (Founder & Managing Partner) and Gil Eyal (Startup Mentor). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
